Advertisement

Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis

Abstract

Background

We aimed to evaluate the construct validity of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) in Australian systemic sclerosis (SSc) patients.

Methods

SSc patients, identified through the Australian Scleroderma Cohort Study database, completed two quality-of-life instruments concurrently, the PROMIS-29 and the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). The construct validity of the PROMIS-29 was assessed by the correlations between the PROMIS-29 and the SF-36 and Health Assessment Questionnaire Disability Index (HAQ-DI). Cronbach’s alpha was used to test the internal reliability of all instruments in Australian SSc patients and non-parametric correlation, including Spearman’s correlation, was used to test the construct validity of PROMIS-29 against the SF-36 and HAQ-DI.

Results

A total of 477 completed questionnaires were returned, equating to a response rate of 59.6%. The mean (±SD) age of respondents at the time of the survey was 64.1 (±11.1) years. They were predominantly female (87.4%), with limited disease subtype (lcSSc) (77.8%) and long disease duration from onset of first non-Raynaud’s phenomenon symptom at the time of survey (10.9 ± 11.1 years). For the correlation analysis between the PROMIS-29 and the legacy instruments, all Spearman correlation coefficients were in the logical direction and highly significant suggesting that the PROMIS-29 is a good alternative to other validated measures of disease burden.

Conclusions

Our study indicates that the PROMIS-29 questionnaire is a valid instrument for measuring health-related quality of life in Australian females with lcSSc of long duration.

Post author correction

Article Type: ORIGINAL RESEARCH ARTICLE

Article Subject: Epidemiology and Diagnostic Methods

DOI:10.5301/jsrd.5000243

Authors

Kathleen Morrisroe, Wendy Stevens, Molla Huq, Joanne Sahhar, Gene-Siew Ngian, Jane Zochling, Janet Roddy, the Australian Scleroderma Interest Group (ASIG) Susanna Proudman, Mandana Nikpour,

Article History

Disclosures

Financial support: This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. Dr. Morrisroe holds an NHMRC Scholarship (APP1113954). Dr. Nikpour holds an NHMRC Fellowship (APP1071735).
Conflict of interest: None of the authors has financial interest related to this study to disclose.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Medicine, The University of Melbourne at St. Vincent’s Hospital, Melbourne, Victoria - Australia
  • Department of Rheumatology, St. Vincent’s Hospital, Melbourne, Victoria - Australia
  • Monash University and Monash Health, Victoria - Australia
  • Department of Rheumatology, Menzies Institute for Medical Research, Hobart - Australia
  • Department of Rheumatology, Royal Perth Hospital, Perth - Australia
  • Rheumatology Unit, Royal Adelaide Hospital, Adelaide, SA - Australia
  • Discipline of Medicine, University of Adelaide, Adelaide, SA - Australia
  • The complete list of investigators in the Australian Scleroderma Interest Group (ASIG) is available in the Acknowledgements section

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

This article has supplementary materials available to download.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.